1 - 199 of 199
Title Published in Access level OA Policy Year Views Downloads
Rhumatismes inflammatoires : où en est-on avec les JAK-inhibiteurs ?Rheuma Plus / Schweiz
accessLevelPublic
2025 10 73
Identification of individuals at high risk of developing rheumatoid arthritis : a balanced random forest model in a cohort of 1544 first-degree relativesRMD open
accessLevelPublic
2025 15 38
ReplyArthritis & rheumatology
accessLevelRestricted
2025 10 0
Antibiotics in inflammatory arthritis and background population one year before and after diagnosis : a nationwide drug utilization studyRheumatology
accessLevelPublic
2025 14 5
When borders impact science : what is the future of European rheumatology research ?Annals of the rheumatic diseases
accessLevelRestricted
2025 5 0
Incidence of major adverse cardiovascular events in patients with rheumatoid arthritis treated with Janus kinase inhibitors compared to biologic disease-modifying antirheumatic drugs : data from an international collaboration of registries (the "JAK-pot" study)Arthritis & rheumatology
accessLevelPublic
2025 89 62
Antirheumatic drugs in reproduction, pregnancy, and lactation : a systematic literature review informing the 2024 update of the EULAR recommendationsAnnals of the rheumatic diseases
accessLevelPublic
2025 20 706
The epidemiology of RANature reviews. Rheumatology
accessLevelRestricted
2025 6 0
Systematic literature review and meta-analysis informing the EULAR points to consider on the initiation of targeted therapies in patients with inflammatory arthritis and a history of cancerAnnals of the rheumatic diseases
accessLevelRestricted
2025 50 0
Rhumatologie : ce qui a changé en 2023Revue médicale suisse
accessLevelPublic
2024 53 42
Comparative effectiveness of biologics in patients with rheumatoid arthritis stratified by body mass index : a cohort study in a Swiss registryBMJ open
accessLevelPublic
2024 11 31
Rotation or change of biotherapy after TNF blocker treatment failure for axial spondyloarthritis : the ROC-SpA study, a randomised controlled study protocolBMJ open
accessLevelPublic
2024 9 75
Anti-Apolipoprotein A-1 IgG, incident cardiovascular events and lipid paradox inrheumatoid arthritisESC (Europan Society of Cardiology) Congress 2024
2024 6 0
Gut microbiome and intestinal inflammation in preclinical stages of rheumatoid arthritisRMD open
accessLevelPublic
2024 106 78
Anti-apolipoprotein A-1 IgG, incident cardiovascular events and lipid paradox in rheumatoid arthritis92nd EAS (European Atherosclerosis Society) Congress
2024 9 0
Evaluation of discontinuation for adverse events of JAK inhibitors and bDMARDs in an international collaboration of rheumatoid arthritis registers (the ‘JAK-pot’ study)Annals of the rheumatic diseases
accessLevelPublic
2024 98 82
Explainable deep learning for disease activity prediction in chronic inflammatory joint diseasesPLOS digital health
accessLevelPublic
2024 8 16
Anti-apolipoprotein A-1 IgG, incident cardiovascular events, and lipid paradox in rheumatoid arthritisFrontiers in cardiovascular medicine
accessLevelPublic
2024 119 179
Comparative effectiveness of baricitinib and alternative biological DMARDs in a Swiss cohort study of patients with RABMJ open
accessLevelPublic
2024 136 113
Tofacitinib Monotherapy in Rheumatoid Arthritis : Clinical Trials and Real-World Data Contextualization of Patients, Efficacy, and Treatment RetentionOpen access rheumatology
accessLevelPublic
2024 8 16
Oral glucocorticoid use in patients with rheumatoid arthritis initiating TNF-inhibitors, tocilizumab or abatacept: Results from the international TOCERRA and PANABA observational collaborative studiesJoint bone spine
accessLevelPublic
2024 101 117
2024 EULAR points to consider on the initiation of targeted therapies in patients with inflammatory arthritis and a history of cancerAnnals of the rheumatic diseases
accessLevelPublic
2024 58 984
Concomitant Sjögren's disease as a biomarker for treatment effectiveness in rheumatoid arthritis - results from the Swiss clinical quality management cohortArthritis research & therapy
accessLevelPublic
2024 9 40
Brief report: can COVID-19 infection trigger rheumatoid arthritis-associated autoimmunity in individuals at risk for the disease? A nested cohort studyFrontiers in medicine
accessLevelPublic
2023 68 92
Longitudinal associations between body mass index and changes in disease activity and radiographic progression in rheumatoid arthritis patients treated with infliximabRMD open
accessLevelPublic
2023 85 46
The Symptoms in Persons At Risk of Rheumatoid Arthritis (SPARRA) questionnaire: predicting clinical arthritis developmentScandinavian journal of rheumatology
accessLevelPublic
2023 148 159
A potential role for chlamydial infection in rheumatoid arthritis developmentRheumatology
accessLevelPublic
2023 92 201
Comparison of drug retention of TNF inhibitors, other biologics and JAK inhibitors in RA patients who discontinued JAK inhibitor therapyRheumatology
accessLevelPublic
2023 82 183
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 updateAnnals of the rheumatic diseases
accessLevelPublic
2023 260 275
Characterization of serum biomarkers and antibody responses against Prevotella spp. in preclinical and new-onset phase of rheumatic diseasesFrontiers in cellular and infection microbiology
accessLevelPublic
2023 113 123
Brief report : assessment of mucosal barrier integrity using serological biomarkers in preclinical stages of rheumatoid arthritisFrontiers in immunology
accessLevelPublic
2023 191 279
Safety outcomes in patients with rheumatoid arthritis treated with abatacept: results from a multinational surveillance study across seven European registriesArthritis research & therapy
accessLevelPublic
2023 68 158
Impact of SARS-CoV2 infection on anti-apolipoprotein A-1 IgG response in inflammatory rheumatic diseasesFrontiers in immunology
accessLevelPublic
2023 131 87
Management of giant-cell arteritis in Switzerland: an online national surveySwiss medical weekly
accessLevelPublic
2023 231 292
Omicron-specific cytotoxic t-cell responses after a third dose of mrna covid-19 vaccine among patients with multiple sclerosis treated with ocrelizumabJAMA neurology
accessLevelPublic
2022 249 173
EULAR points to consider when analysing and reporting comparative effectiveness research using observational data in rheumatologyAnnals of the rheumatic diseases
accessLevelPublic
2022 210 80
After JAK inhibitor failure: to cycle or to switch, that is the question – data from the JAK-pot collaboration of registriesAnnals of the rheumatic diseases
accessLevelPublic
2022 268 469
Nouveautés en médecine 2021 - RhumatologieRevue médicale suisse
accessLevelPublic
2022 296 249
Accounting for missing data caused by drug cessation in observational comparative effectiveness research: a simulation studyAnnals of the rheumatic diseases
accessLevelPublic
2022 293 138
Periodontitis in first degree-relatives of individuals with rheumatoid arthritis: a short narrative reviewFrontiers in oral health
accessLevelPublic
2022 205 112
Prévention vaccinale chez les patients avec des maladies rhumatismalesRevue médicale suisse
accessLevelPublic
2022 111 132
Lower odds of remission among women with rheumatoid arthritis: A cohort study in the Swiss Clinical Quality Management cohortPloS one
accessLevelPublic
2022 72 62
Combining individual patient data from randomized and non-randomized studies to predict real-world effectiveness of interventionsStatistical methods in medical research
accessLevelPublic
2022 150 130
Global epidemiology of rheumatoid arthritisNature reviews. Rheumatology
accessLevelRestricted
2022 357 1
Robust T-Cell Responses in Anti-CD20 Treated Patients Following COVID-19 Vaccination: A Prospective Cohort StudyClinical infectious diseases
accessLevelPublic
2022 233 66
Effectiveness of TNF-inhibitors, abatacept, IL6-inhibitors and JAK-inhibitors in 31 846 patients with rheumatoid arthritis in 19 registers from the ‘JAK-pot’ collaborationAnnals of the rheumatic diseases
accessLevelPublic
2022 339 99
Type of mRNA COVID-19 vaccine and immunomodulatory treatment influence humoral immunogenicity in patients with inflammatory rheumatic diseasesFrontiers in immunology
accessLevelPublic
2022 204 91
Interruptions of biological and targeted synthetic disease-modifying antirheumatic drugs in rheumatoid arthritis : a descriptive cohort study assessing trends in patient characteristics in SwitzerlandBMJ open
accessLevelPublic
2022 62 55
Editoria : The interplay between the oral microbiota and rheumatoid arthritisFrontiers in oral health
accessLevelPublic
2022 110 83
Predictive value of anti-CarP and anti-PAD3 antibodies alone or in combination with RF and ACPA on the severity of rheumatoid arthritisRheumatology
accessLevelPublic
2021 379 476
EULAR points to consider for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitorsAnnals of the Rheumatic Diseases
accessLevelPublic
2021 254 736
Cohort profile: SCREEN-RA: design, methods and perspectives of a Swiss cohort study of first-degree relatives of patients with rheumatoid arthritisBMJ Open
accessLevelPublic
2021 355 202
Prediction of sustained biologic and targeted synthetic DMARD-free remission in rheumatoid arthritis patientsRheumatology advances in practice
accessLevelPublic
2021 161 98
Comparison of psoriatic arthritis and rheumatoid arthritis patients across body mass index categories in SwitzerlandJournal of Clinical Medicine
accessLevelPublic
2021 225 119
Identification of biological pathways specific to phases preceding rheumatoid arthritis development through gene expression profilingInternational Journal of Immunogenetics
accessLevelRestricted
2021 216 0
Analysing and reporting of observational data: a systematic review informing the EULAR points to consider when analysing and reporting comparative effectiveness research with observational data in rheumatologyRMD open
accessLevelPublic
2021 265 159
Impact of the COVID-19 pandemic on the disease course of patients with inflammatory rheumatic diseases: results from the Swiss Clinical Quality Management cohortAnnals of the Rheumatic Diseases
accessLevelPublic
2021 187 254
Greater trochanteric pain syndrome: predicting who will respond to a local glucocorticoid injectionScandinavian Journal of Rheumatology
accessLevelRestricted
2021 259 0
Associations between serum antibodies to periodontal pathogens and preclinical phases of rheumatoid arthritisRheumatology
accessLevelRestricted
2021 263 0
Primary and secondary non-response: in need of operational definitions in observational studiesAnnals of the Rheumatic Diseases
accessLevelPublic
2021 253 93
Influence of COVID-19 pandemic on decisions for the management of people with inflammatory rheumatic and musculoskeletal diseases: a survey among EULAR countriesAnnals of the Rheumatic Diseases
accessLevelPublic
2021 210 317
The impact of seropositivity on the effectiveness of biologic anti-rheumatic agents: results from a collaboration of 16 registriesRheumatology
accessLevelRestricted
2021 246 0
Mazzotti reaction: Ivermectin-associated polyarthritis after delayed scabies treatment. Case report and review of the literatureThérapie
accessLevelRestricted
2021 1,170 1
Cognitive-bias modification intervention to improve physical activity in patients following a rehabilitation programme: protocol for the randomised controlled IMPACT trialBMJ open
accessLevelPublic
2021 253 225
Impact of assessing patient-reported outcomes with mobile apps on patient–provider interactionRMD Open
accessLevelPublic
2021 261 78
Incidence of COVID-19 in patients treated with infliximab compared with patients treated with rituximabRMD open
accessLevelPublic
2021 263 117
Personalized prediction of disease activity in patients with rheumatoid arthritis using an adaptive deep neural networkPLOS ONE
accessLevelPublic
2021 296 216
EULAR points to consider for conducting clinical trials and observational studies in individuals at risk of rheumatoid arthritisAnnals of the Rheumatic Diseases
accessLevelPublic
2021 374 115
Is the prevention of rheumatoid arthritis possible?Clinical Rheumatology
accessLevelRestricted
2020 183 0
Serum calprotectin: a promising biomarker in rheumatoid arthritis and axial spondyloarthritisArthritis Research and Therapy
accessLevelPublic
2020 415 472
EULAR points to consider for the use of big data in rheumatic and musculoskeletal diseasesAnnals of the Rheumatic Diseases
accessLevelRestricted
2020 351 0
Associations between gut microbiota and genetic risk for rheumatoid arthritis in the absence of disease: a cross-sectional studyThe Lancet. Rheumatology
accessLevelPublic
2020 247 256
smarter medicine: liste Top-5 pour le traitement des rhumatismesBulletin des médecins suisses
accessLevelPublic
2020 119 74
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 updateAnnals of the Rheumatic Diseases
accessLevelPublic
2020 489 324
Measuring ACPA in the general population or primary care: is it useful?RMD Open
accessLevelPublic
2020 241 193
Mini-Review: Human Microbiome and Rheumatic DiseasesFrontiers in cellular and infection microbiology
accessLevelPublic
2020 195 227
Preferences for treatments to prevent rheumatoid arthritis in Canada and the influence of shared decision-makingClinical Rheumatology
accessLevelRestricted
2020 207 0
Predictive factors of treatment persistence in rheumatoid arthritisJoint, Bone, Spine
accessLevelPublic
2020 430 678
Comparative effectiveness of antitumour necrosis factor agents, biologics with an alternative mode of action and tofacitinib in an observational cohort of patients with rheumatoid arthritis in SwitzerlandRMD Open
accessLevelPublic
2020 221 108
Discordances between clinical and ultrasound measurements of disease activity among RA patients followed in real lifeJoint, Bone, Spine
accessLevelRestricted
2020 362 0
The role of nutritional factors and intestinal microbiota in rheumatoid arthritis developmentNutrients
accessLevelPublic
2020 171 203
Detection of circulating highly expanded T-cell clones in at-risk individuals for rheumatoid arthritis before the clinical onset of the diseaseRheumatology
accessLevelRestricted
2020 331 9
Periodontal status correlates with anti‐citrullinated protein antibodies in first‐degree relatives of individuals with rheumatoid arthritisJournal of Clinical Periodontology
accessLevelRestricted
2019 425 2
Presence of anti-cyclic citrullinated peptide antibodies is associated with better treatment response to abatacept but not to TNF inhibitors in patients with rheumatoid arthritis: a meta-analysisClinical and Experimental Rheumatology
accessLevelPublic
2019 385 213
Drug retention of biological DMARD in rheumatoid arthritis patients: the role of baseline characteristics and disease evolutionRheumatology
accessLevelRestricted
2019 374 0
EULAR points to consider for the development, evaluation and implementation of mobile health applications aiding self-management in people living with rheumatic and musculoskeletal diseasesRMD Open
accessLevelPublic
2019 336 211
Imputing missing data of function and disease activity in rheumatoid arthritis registers: what is the best technique?RMD Open
accessLevelPublic
2019 335 152
Menopause and possible effect on association between age and anticyclic citrullinated peptide antibodies in women at risk of rheumatoid arthritisJournal of Rheumatology
accessLevelRestricted
2019 302 0
Synovitis in rheumatoid arthritis detected by grey scale ultrasound predicts the development of erosions over the next three yearsRheumatology
accessLevelPublic
2019 315 199
Glucocorticoid injections for greater trochanteric pain syndrome: a randomised double-blind placebo-controlled (GLUTEAL) trialClinical Rheumatology
accessLevelRestricted
2019 316 0
The links of hepcidin and erythropoietin in the interplay of inflammation and iron deficiency in a large observational study of rheumatoid arthritisBritish Journal of Haematology
accessLevelRestricted
2019 259 0
Role of reproductive and menopausal factors in functional and structural progression of rheumatoid arthritis: results from the SCQM cohortRheumatology
accessLevelRestricted
2019 271 0
2018 EULAR recommendations for a core data set to support observational research and clinical care in giant cell arteritisAnnals of the Rheumatic Diseases
accessLevelPublic
2019 347 307
Towards standardized patient reported physical function outcome reporting: linking ten commonly used questionnaires to a common metricQuality of Life Research
accessLevelPublic
2019 273 166
Patients with rheumatoid arthritis facing sick leave or work disability meet varying regulations: a study among rheumatologists and patients from 44 European countriesAnnals of the Rheumatic Diseases
accessLevelRestricted
2019 368 0
Ultrasound is not associated with the presence of systemic autoimmunity or symptoms in individuals at risk for rheumatoid arthritisRMD Open
accessLevelPublic
2019 340 122
Preventing rheumatoid arthritis: preferences for and predicted uptake of preventive treatments among high risk individualsPLOS ONE
accessLevelPublic
2019 308 254
Current status of use of big data and artificial intelligence in RMDs: a systematic literature review informing EULAR recommendationsRMD Open
accessLevelPublic
2019 345 160
Prevotella copri in individuals at risk for rheumatoid arthritisAnnals of the Rheumatic Diseases
2019 469 0
Preferences of Patients and At-risk Individuals for Preventive Approaches to Rheumatoid ArthritisClinical Therapeutics
accessLevelRestricted
2019 295 1
Intestinal dysbiosis in RA development: difficulty of establishing causality. Response to: 'Non-causal association of gut microbiome on the risk of rheumatoid arthritis: a Mendelian randomisation study' by InamoAnnals of the Rheumatic Diseases
accessLevelRestricted
2019 343 4
Lessons learned from rheumatoid arthritis registriesJoint, Bone, Spine
accessLevelRestricted
2018 445 3
Initial validation and results of the Symptoms in Persons At Risk of Rheumatoid Arthritis (SPARRA) questionnaire: a EULAR projectRMD Open
accessLevelPublic
2018 464 196
Workforce requirements in rheumatology: a systematic literature review informing the development of a workforce prediction risk of bias tool and the EULAR points to considerRMD Open
accessLevelPublic
2018 320 240
EULAR 'points to consider' for the conduction of workforce requirement studies in rheumatologyRMD Open
accessLevelPublic
2018 322 247
Response to Tumor Necrosis Factor Inhibition in Male and Female Patients with Ankylosing Spondylitis: Data from a Swiss CohortJournal of Rheumatology
accessLevelRestricted
2018 463 1
Prediction of Real-World Drug Effectiveness Prelaunch: Case Study in Rheumatoid ArthritisMedical Decision Making
accessLevelRestricted
2018 475 0
2017 EULAR recommendations for a core data set to support observational research and clinical care in rheumatoid arthritisAnnals of the Rheumatic Diseases
accessLevelRestricted
2018 428 0
Microbiotes et rhumatismes inflammatoiresRevue médicale suisse
accessLevelPublic
2018 500 164
Chagas disease and systemic autoimmune diseases among Bolivian patients in SwitzerlandMemórias do Instituto Oswaldo Cruz
accessLevelPublic
2018 601 226
Low Hemoglobin and Radiographic Damage Progression in Early Rheumatoid Arthritis: Secondary Analysis From a Phase III TrialArthritis Care and Research
accessLevelRestricted
2018 368 1
Incidence and prevalence of major adverse cardiovascular events in rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritisArthritis Care and Research
accessLevelPublic
2018 438 448
Female hormonal factors and the development of anti-citrullinated protein antibodies in women at risk of rheumatoid arthritisRheumatology
accessLevelRestricted
2017 555 5
Risk of invasive melanoma in patients with rheumatoid arthritis treated with biologics: results from a collaborative project of 11 European biologic registersAnnals of the Rheumatic Diseases
accessLevelPublic
2017 503 269
Value of Biomarkers in the Prevention of Rheumatoid ArthritisClinical Pharmacology and Therapeutics
accessLevelRestricted
2017 461 0
The prevalence of anticitrullinated protein antibodies increases with age in healthy individuals at risk for rheumatoid arthritisClinical Rheumatology
accessLevelRestricted
2017 632 3
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 updateAnnals of the Rheumatic Diseases
accessLevelRestricted
2017 483 2
Does addition of glucocorticoids to the initial therapy influence the later course of the disease in patients with early RA? Results from the Swiss prospective observational registry (SCQM)Clinical Rheumatology
accessLevelRestricted
2017 408 0
Presence of IL-17 in synovial fluid identifies a potential inflammatory osteoarthritic phenotypePloS one
accessLevelPublic
2017 562 351
Environmental factors and hormones in the development of rheumatoid arthritisSeminars in Immunopathology
accessLevelRestricted
2017 482 0
Body mass does not impact the clinical response to intravenous abatacept in patients with rheumatoid arthritis. Analysis from the "pan-European registry collaboration for abatacept (PANABA)Clinical Rheumatology
accessLevelRestricted
2017 485 2
The role of female hormonal factors in the development of rheumatoid arthritisRheumatology
accessLevelRestricted
2017 469 0
Differential impact of systemic lupus erythematosus and rheumatoid arthritis on health-related quality of lifeQuality of life research
accessLevelRestricted
2017 527 1
New viral outbreaks: time for rheumatologists to get involved?Rheumatology
accessLevelRestricted
2017 464 0
Impaired response to treatment with tumour necrosis factor α inhibitors in smokers with axial spondyloarthritisAnnals of the rheumatic diseases
accessLevelRestricted
2016 597 0
The Effect of Comedication With a Conventional Synthetic Disease-Modifying Antirheumatic Drug on Drug Retention and Clinical Effectiveness of Anti-Tumor Necrosis Factor Therapy in Patients With Axial SpondyloarthritisArthritis & rheumatology
accessLevelRestricted
2016 532 0
Points to consider for reporting, screening for and preventing selected comorbidities in chronic inflammatory rheumatic diseases in daily practice: a EULAR initiativeAnnals of the Rheumatic Diseases
accessLevelRestricted
2016 457 0
Phase 1 Trials of rVSV Ebola Vaccine in Africa and Europe : Preliminary ReportThe New England journal of medicine
accessLevelPublic
2016 935 285
Low pre-treatment B-cell counts are not a risk factor of infection in patients treated with rituximab for autoimmune diseases: An observational studyJoint, Bone, Spine
accessLevelRestricted
2016 537 0
Preventive Treatments for Rheumatoid Arthritis: Issues Regarding Patient PreferencesCurrent rheumatology reports
accessLevelRestricted
2016 562 1
Brief Report: Association of Rheumatoid Factor and Anti-Citrullinated Protein Antibody Positivity With Better Effectiveness of Abatacept: Results From the Pan-European Registry AnalysisArthritis and Rheumatology
accessLevelRestricted
2016 383 0
Rheumatoid Arthritis Patients after Initiation of a New Biologic Agent: Trajectories of Disease Activity in a Large Multinational Cohort StudyEBioMedicine
accessLevelPublic
2016 488 230
Comparative Efficacy of Novel DMARDs as Monotherapy and in Combination with Methotrexate in Rheumatoid Arthritis Patients with Inadequate Response to Conventional DMARDs: A Network Meta-AnalysisJournal of managed care & specialty pharmacy
accessLevelRestricted
2015 591 0
Effectiveness of biologic DMARDs in monotherapy versus in combination with synthetic DMARDs in rheumatoid arthritis: data from the Swiss Clinical Quality Management RegistryRheumatology
accessLevelRestricted
2015 501 0
The EULAR Study Group for Registers and Observational Drug Studies: comparability of the patient case mix in the European biologic disease modifying anti-rheumatic drug registersRheumatology
accessLevelPublic
2015 602 298
The effect of dose on the safety and immunogenicity of the VSV Ebola candidate vaccine: a randomised double-blind, placebo-controlled phase 1/2 trialLancet. Infectious diseases
accessLevelRestricted
2015 706 0
The new 2010 ACR/EULAR criteria as predictor of clinical and radiographic response in patients with early arthritisClinical rheumatology
accessLevelRestricted
2015 570 0
An Internet-based technique for the identification of persons with symptoms of inflammatory polyarthritis of less than 12 weeksClinical rheumatology
accessLevelRestricted
2015 476 0
Anti-tumor necrosis factor drug survival in axial spondyloarthritis is independent of the classification criteriaRheumatology international
accessLevelRestricted
2015 602 0
Chronic NSAID use and long-term decline of renal function in a prospective rheumatoid arthritis cohort studyAnnals of the rheumatic diseases
accessLevelRestricted
2015 648 0
Rituximab versus an alternative TNF inhibitor in patients with rheumatoid arthritis who failed to respond to a single previous TNF inhibitor: SWITCH-RA, a global, observational, comparative effectiveness studyAnnals of the rheumatic diseases
accessLevelPublic
2015 574 346
The impact of patient heterogeneity and socioeconomic factors on abatacept retention in rheumatoid arthritis across nine European countriesRMD open
accessLevelPublic
2015 483 254
Inflammatory Articular Disease in Patients with Inflammatory Bowel Disease: Result of the Swiss IBD Cohort StudyInflammatory bowel diseases
accessLevelRestricted
2015 495 0
The impact of obesity on the development and progression of rheumatoid arthritisAnnals of the rheumatic diseases
accessLevelRestricted
2014 565 0
Immune-mediated experimental arthritis in IL-33 deficient miceCytokine
accessLevelRestricted
2014 676 0
Prevention of rheumatic diseases: strategies, caveats, and future directionsRheumatic diseases clinics of North America
2014 495 0
Adipokines correlate with pain in lower limb osteoarthritis: different associations in hip and kneeInternational orthopaedics
accessLevelRestricted
2014 583 0
Tocilizumab in the treatment of rheumatoid arthritis: a cost-effectiveness analysis in the UKPharmacoEconomics
accessLevelPublic
2014 530 519
Joint damage progression in patients with rheumatoid arthritis in clinical remission. Do biologics perform better than synthetic antirheumatic drugs?Journal of rheumatology
accessLevelRestricted
2014 527 0
Facteurs de risque pour le développement d'une polyarthrite rhumatoïdeRevue médicale suisse
accessLevelRestricted
2014 534 2
Anaemia may add information to standardised disease activity assessment to predict radiographic damage in rheumatoid arthritis: a prospective cohort studyAnnals of the rheumatic diseases
accessLevelPublic
2014 617 612
Persistence of ultrasound synovitis in patients with rheumatoid arthritis fulfilling the DAS28 and/or the new ACR/EULAR RA remission definitions: results of an observational cohort studyJoint bone spine
accessLevelRestricted
2014 596 0
Methotrexate in chronic-recurrent calcium pyrophosphate deposition disease: no significant effect in a randomized crossover trialArthritis research & therapy
accessLevelPublic
2014 708 252
Complications cardio-vasculaires dans les maladies auto-immunesRevue médicale suisse
accessLevelRestricted
2013 548 1
Disease activity in rheumatoid arthritis patients at initiation of biologic agents and 1 year of treatment: results from the Swiss SCQM registryJoint bone spine
accessLevelRestricted
2013 562 0
Disease severity in K/BxN serum transfer-induced arthritis is not affected by IL-33 deficiencyArthritis research & therapy
accessLevelPublic
2013 647 296
Primary prevention of rheumatoid arthritis: a qualitative study in a high-risk populationJoint bone spine
accessLevelRestricted
2013 629 1
Do synovial leptin levels correlate with pain in end stage arthritis?International orthopaedics
accessLevelPublic
2013 679 228
Smoking and spondyloarthritisJoint bone spine
accessLevelRestricted
2013 567 1
The importance of early treatment for the prognosis of rheumatoid arthritisSchweizerische medizinische Wochenschrift
accessLevelPublic
2013 658 327
Adalimumab in acute sciatica reduces the long-term need for surgery: a 3-year follow-up of a randomised double-blind placebo-controlled trialAnnals of the rheumatic diseases
accessLevelRestricted
2012 676 0
Evolution of radiographic joint damage in rituximab-treated versus TNF-treated rheumatoid arthritis cases with inadequate response to TNF antagonistsAnnals of the rheumatic diseases
accessLevelPublic
2012 567 435
Evaluation of cardiovascular risk in patients with rheumatoid arthritis: do cardiovascular biomarkers offer added predictive ability over established clinical risk scores?Arthritis care & research
accessLevelRestricted
2012 698 0
Pain as an important predictor of psychosocial health in patients with rheumatoid arthritisArthritis care & research
accessLevelPrivate
2012 664 0
EULAR recommendations for terminology and research in individuals at risk of rheumatoid arthritis: report from the Study Group for Risk Factors for Rheumatoid ArthritisAnnals of the rheumatic diseases
accessLevelPublic
2012 703 584
Differential drug retention between anti-TNF agents and alternative biological agents after inadequate response to an anti-TNF agent in rheumatoid arthritis patientsAnnals of the rheumatic diseases
accessLevelRestricted
2012 682 0
Spontaneous secretion of interleukin-17 and -22 by human cervical cells in Chlamydia trachomatis infectionMicrobes and infection
accessLevelRestricted
2011 618 0
Patient repositioning reproducibility of joint space with (JSW) measurements on hand radiographsArthritis care & research
accessLevelRestricted
2011 485 0
Symptomatic effects of chondroitin 4 and chondroitin 6 sulfate on hand osteoarthritis: a randomized, double-blind, placebo-controlled clinical trial at a single centerArthritis and rheumatism
accessLevelRestricted
2011 689 0
The long-term impact of early treatment of rheumatoid arthritis on radiographic progression: a population-based cohort studyRheumatology
accessLevelRestricted
2011 610 0
Autoimmunity and inflammation are independent of class II transactivator type PIV-dependent class II major histocompatibility complex expression in peripheral tissues during collagen-induced arthritisArthritis and rheumatism
accessLevelRestricted
2011 650 0
Do new biologics meet the unmet medical need in rheumatoid arthritis? Safety and efficacy of abatacept following B-cell depletionRheumatology
accessLevelRestricted
2011 511 0
Indirect comparisons of the efficacy of biological antirheumatic agents in rheumatoid arthritis in patients with an inadequate response to conventional disease-modifying antirheumatic drugs or to an anti-tumour necrosis factor agent: a meta-analysisAnnals of the rheumatic diseases
accessLevelRestricted
2011 589 0
EULAR points to consider when establishing, analysing and reporting safety data of biologics registers in rheumatologyAnnals of the rheumatic diseases
accessLevelRestricted
2010 593 0
Osteoarthritis: Small studies overestimate the benefit of therapies for OANature reviews. Rheumatology
accessLevelRestricted
2010 689 0
Influence of anti-infliximab antibodies and residual infliximab concentrations on the occurrence of acquired drug resistance to infliximab in rheumatoid arthritis patientsJoint bone spine
accessLevelRestricted
2010 620 0
Diagnostic value of anti-cyclic citrullinated peptides and association with HLA-DRB1 shared epitope alleles in African rheumatoid arthritis patientsArthritis research & therapy
accessLevelPublic
2010 794 579
Anti-apolipoprotein A-1 IgG predicts major cardiovascular events in patients with rheumatoid arthritisArthritis and rheumatism
accessLevelRestricted
2010 908 3
Cost-effectiveness of biologics in early rheumatoid arthritisAnnals of internal medicine
2010 524 0
The effect of alcohol on radiographic progression in rheumatoid arthritisArthritis and rheumatism
accessLevelRestricted
2010 598 0
Which subgroup of patients with rheumatoid arthritis benefits from switching to rituximab versus alternative anti-tumour necrosis factor (TNF) agents after previous failure of an anti-TNF agent?Annals of the rheumatic diseases
accessLevelRestricted
2010 599 0
Comparative effectiveness of rheumatoid arthritis therapiesCurrent rheumatology reports
accessLevelRestricted
2010 527 0
Swiss consensus statement: Recommendations for optimising re-treatment with MabThera (rituximab) in rheumatoid arthritisSchweizerische medizinische Wochenschrift
2010 570 0
A comparison of patient characteristics and outcomes in selected European and U.S. rheumatoid arthritis registriesSeminars in arthritis and rheumatism
accessLevelRestricted
2010 634 0
Adalimumab in severe and acute sciatica: a multicenter, randomized, double-blind, placebo-controlled trialArthritis and rheumatism
accessLevelRestricted
2010 677 0
Inhibition of interleukin-33 signaling attenuates the severity of experimental arthritisArthritis and rheumatism
accessLevelRestricted
2009 660 0
Clinical experience with mycophenolate mofetil in systemic autoimmune conditions refractory to common immunosuppressive therapiesSchweizerische medizinische Wochenschrift
accessLevelPublic
2009 635 400
Comparison of drug retention rates and causes of drug discontinuation between anti-tumor necrosis factor agents in rheumatoid arthritisArthritis and rheumatism
accessLevelRestricted
2009 630 0
BMI and severity of clinical and radiographic signs of hip osteoarthritisObesity
accessLevelRestricted
2009 991 0
Influence of cytokine inhibitors on concentration and activity of MMP-1 and MMP-3 in disc herniationArthritis research & therapy
accessLevelPublic
2009 667 255
The effectiveness of leflunomide as a co-therapy of tumour necrosis factor inhibitors in rheumatoid arthritis: a population-based studyAnnals of the rheumatic diseases
accessLevelRestricted
2009 613 0
Elevated levels of tumor necrosis factor-alpha in periradicular fat tissue in patients with radiculopathy from herniated discSpine
accessLevelRestricted
2008 679 0
At the horizon of innovative therapy in rheumatology: new biologic agentsCurrent opinion in rheumatology
accessLevelRestricted
2008 631 0
Primer: strengths and weaknesses of meta-analysisNature clinical practice rheumatology
accessLevelRestricted
2008 676 0
Neutral functional realignment orthosis prevents hand pain in patients with subacute stroke: a randomized trialArchives of physical medicine and rehabilitation
accessLevelRestricted
2008 611 0
B cell depletion may be more effective than switching to an alternative anti-tumor necrosis factor agent in rheumatoid arthritis patients with inadequate response to anti-tumor necrosis factor agentsArthritis and rheumatism
accessLevelRestricted
2007 179 1
Occupational silica and solvent exposures and risk of systemic lupus erythematosus in urban womenArthritis and rheumatism
accessLevelPublic
2006 248 610
Fibromyalgia: a randomised, controlled trial of a treatment programme based on self managementAnnals of the rheumatic diseases
accessLevelRestricted
2004 510 2
Neurophysiologic evidence for a central sensitization in patients with fibromyalgiaArthritis and rheumatism
accessLevelPublic
2003 550 884
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack